WXIBF (WuXi Biologics (Cayman)) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WXIBF WuXi Biologics (Cayman) Inc WXIBF
97 GF Score
Price $4.60
GF Value $5.14
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is WuXi Biologics (Cayman) Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

WuXi Biologics (Cayman) Quality Rank Related Terms

WXIBF
97GF Score
WuXi Biologics (Cayman) Inc WXIBF
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is WuXi Biologics (Cayman) (WXIBF) Overvalued in 2026?

Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be undervalued. The current stock price of $4.60 is trading 10.5% below its estimated GF Value™ of $5.14. GuruFocus considers WuXi Biologics (Cayman) to be Modestly Undervalued.

Key valuation signals for WXIBF:

  • Quality Rank:
  • GF Value™: $5.14 vs. price of $4.60 (10.5% below fair value)
  • GF Score™: 97/100 with 3 warning signs

No single metric tells the full story. See the WXIBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

WuXi Biologics (Cayman) Business Description

Address No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
97GF Score

Get the complete analysis for WXIBF

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.60
Price
$5.14
GF Value